New: NCI-funded clinical trial search
Mednet Logo
CommunityRadiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How would you treat and delineate target volume for a pT1N2 NSCLC after wedge resection with clear margins?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Cleveland Clinic

In a patient who has undergone a wedge resection and who has negative margins, I do not see an indication for radiotherapy to the residual primary site or staple line, inasmuch as the surgical approach is not standard of care in operable patients. If wedge is done in a high risk operable patient, I ...

How would you approach the treatment of a patient with a history of cutaneous melanoma and only overt site of disease being a bulky level III axillary lymph node?

3 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Florida

Surgery and postop RT.

What dose-fractionation scheme do you recommend for the treatment of leukemia cutis?

2 Answers

Mednet Member
Radiation Oncology · UMass Memorial Medical Group

Leukemia cutis (LC) is a form of cutaneous extra-medullary leukemia that confers a relatively poor prognosis, with a median survival of <12 months. Since most of these patients have additional sites of involvement (spleen, liver, CNS), the mainstay of treatment of EMD leukemias is still considered t...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What is your hemoglobin transfusion threshold for asymptomatic pediatric solid tumor patients during radiation?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Northwestern University Feinberg School of Medicine

We aim for a Hb of 10g/dL whenever possible. This is not based on any data from pediatrics, but from data in adult patients (Prognostic value of hemoglobin concentrations and blood transfusions in a retrospective study of 386 patients).

In a patient with newly diagnosed anal squamous cell carcinoma, who has an extensive history of active autoimmune disease including Crohn's, Lupus, and arthropathies on multiple therapies, would you forgo radiation therapy and proceed to APR upfront?

2
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Yale School of Medicine

I've treated patients like this with standard chemoradiation, and while the GI toxicities are certainly increased, we have gotten them through curative treatment with aggressive symptom management. I would carefully counsel patients on APR vs increased risks of chemoradiation in the autoimmune conte...

Can liquid biopsy be substituted for tissue biopsy in a lung mass that is radiologically suspicious for primary lung cancer when CT-guided biopsy cannot be done?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center

Generally, the utility of liquid biopsy remains in the ability to provide genomic information from cfDNA. A liquid biopsy will not provide a definitive tissue diagnosis and does not provide information about histology. When a histologic diagnosis is made with biopsy or FNA but the sample is insuffic...

Do you stop treatment for a prostate cancer patient diagnosed with acute radiation proctitis with significant pain?

4
3 Answers

Mednet Member
Radiation Oncology · Stony Brook University School of Medicine

I would first check the treatment fields and treatment setup to ensure that there isn't excessive dose going to the anorectum. As with all toxicities in radiation oncology, one must exclude other possible reasons for the anorectal pain such as hemorrhoids, infection, or inflammatory bowel disease. I...

How do you counsel patients who are candidates for a clinical trial regarding their options?

2 Answers

Mednet MemberInvited Expert
Gynecologic Oncology · Virginia Commonwealth University Health System

I typically discuss the option with patients as early as possible in their diagnosis, and explain that at some point during their treatment they may become a candidate for a clinical trial. I discuss resources to look into clinical trials and what they mean for patients. We discuss patient website r...

How do you approach multiply recurrent early-stage oral tongue SCC despite multiple resections?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Florida

Surgery and postop RT.

Would you consider XRT for relapsed seminoma in the retroperitoneum, pelvis, and mediastinum with good response after chemo, but with poor kidney function?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network

If the patient has responded to chemo and has residual mass, most likely it is benign with fibrosis and PET scan in this setting can help as has very high negative predictive value.